Healthcare AI Due Diligence

Summary

A global private equity firm engaged us to conduct technical due diligence on a prospective investment in an AI-powered healthcare technology company. The target sold into risk adjustment, quality improvement, member management, and clinical intelligence.

The central question was not whether the company used AI. It was how much of the AI mattered: whether machine learning materially improved coding accuracy and efficiency, whether the clinical intelligence product had real predictive power, and how much of the stack was proprietary rather than a wrapper over third-party services.

Case Study: Technical Due Diligence for an AI Investment in Healthcare

Client: A global private equity firm.

Engagement: Independent technical due diligence supporting an investment decision.

What We Examined

The target’s products spanned risk adjustment, quality improvement, member management, and clinical intelligence. Our assessment covered:

• Product roadmap and the organization’s demonstrated ability to deliver against it
• Risk adjustment performance, measured on accuracy and completion
• The multi-tenant architecture and whether it would hold at the projected scale
• Integration status of prior acquisitions, and what remained unfinished
• NLP and machine learning capability, and where it sat against the competitive set
• How AI models were designed, trained, and evaluated
• The proportion of the AI stack that was proprietary versus licensed
• Data maturity, and the strength of the internal data science and ML team

Why It Mattered

Investment theses in this category tend to rest on the assumption that AI capability is durable and defensible. That assumption is worth testing directly. A company can produce impressive product demonstrations while depending almost entirely on third-party model providers, which changes both the margin profile and the competitive moat.

Our work gave the firm an independent read on the technology, the intellectual property, the security posture, and the engineering organization, along with the technical debt and integration risk that would become the acquirer’s problem after close.

Outcome

The firm went into its investment decision with a clear view of what it would be buying: which capabilities were genuinely differentiated, which were commodity, what remediation the platform would require, and whether the engineering organization could deliver the roadmap the thesis depended on.

Client and target identities are withheld under confidentiality.